EURO-Online login
- New to EURO? Create an account
- I forgot my username and/or my password.
- Help with cookies
(important for IE8 users)
49. Bronze, silver or gold? What’s the added value of investing more in the analysis of medical technologies?
Invited abstract in session TA-13: OR Innovations in Policy Making - B, stream Soft OR and Problem Structuring Methods.
Tuesday, 8:30-10:00Room: 15 (building: 116)
Authors (first author is the speaker)
| 1. | Alec Morton
|
| Management Science, University of Strathclyde | |
| 2. | Jamaica Briones
|
| National University of Singapore | |
| 3. | Pete Baker
|
| Center for Global Development |
Abstract
Health Technology Assessment (HTA) is an applied discipline which involves providing support to decision makers about the cost-effectiveness and budget impact of medical technologies, with a view to informing decisions about reimbursement in a given country’s health system. However, HTA is itself resource-intensive, and requires analytic skills which may be scarce, particularly in low and middle-income countries. In response, many countries have between explored with “adaptive” HTAs (aHTAs). The idea in an aHTA is for analysts in a target country to adapt the analysis and findings from HTAs from other countries, rather than undertaking HTA de novo. aHTA is thus less-resource intensive and quicker than full HTA, but at the expense of lower contextual relevance. Drawing on systematic reviews and meta-analyses for a number of medical technologies, we run a series of simulations to quantify the financial and health loss of using aHTA for a typical country for a range of cost-effectiveness thresholds, and to explore the factors which drive high losses. This work is a staging post to building an optimisation model which would support a country to optimise its HTA budget across full and adaptive HTAs.
Keywords
- Health Care
Status: accepted
Back to the list of papers